Leerink Partners Reiterates a Buy on Geron Corporation (GERN), Keeps the PT

Geron Corporation (NASDAQ:GERN) is one of the Most Oversold Penny Stocks to Buy Now. On August 12, Faisal Khurshid, an analyst from Leerink Partners, reiterated a Buy rating on Geron Corporation (NASDAQ:GERN) with a price target of $3.

The analyst noted that the company is taking bold steps to overcome the challenges in launching its new drug called Rytelo. Khurshid also noted the appointment of new CEO, Harout Semerjian, who brings relevant experience in hematology. The analyst sees this as a positive move toward the successful launch of Rytelo.

Moreover, the management remains optimistic regarding steady growth, and the recent second-quarter results have also shown a significant increase in demand.

Geron Corporation (NASDAQ:GERN) is a biopharmaceutical company focused on developing treatments for blood disorders.

While we acknowledge the potential of GERN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.